Study of porcine and human isophane (NPH) insulins in normal subjects
β Scribed by D. R. Owens; I. R. Jones; A. J. Birtwell; C. T. R. Burge; S. Luzio; C. J. Davies; P. Heyburn; L. G. Heding
- Publisher
- Springer
- Year
- 1984
- Tongue
- English
- Weight
- 542 KB
- Volume
- 26
- Category
- Article
- ISSN
- 0012-186X
No coin nor oath required. For personal study only.
β¦ Synopsis
The plasma glucose, C-peptide and insulin responses to subcutaneously administered highly purified porcine, 'semi-synthetic' and 'biosynthetic' human isophane (NPH) insulin and diluting medium as control in normal male subjects were evaluated. Porcine and semi-synthetic human NPH insulins were administered at two dose levels of 0.15 and 0.30 U/kg body weight and biosynthetic human NPH at 0.15 U/kg body weight only. At the low dose level the three insulin preparations resulted in a similar maximal hypoglycaemic effect within 3-5 h after administration. However, over the remainder of the 11 h post-injection period, the plasma glucose level was lower after semi-synthetic human insulin. In contrast, at the 0.30 U/kg dose level, there was no difference in the early or late hypoglycaemic response between porcine and semi-synthetic human NPH insulins of equivalent pharmaceutical formulation. The clinical relevance of these findings needs further evaluation. The data suggest that for the 'intermediate-acting' NPH insulin preparations, both the species of insulin, nature and quantity of the retarding protein and their subsequent interaction may determine their time-action characteristics.
π SIMILAR VOLUMES
In the present study insulin binding properties of human semi-synthetic and porcine insulin were compared in Type 1 (insulin-dependent) diabetic patients treated from the onset of their disease either with human semi-synthetic insulin (n = 12) or porcine insulin (n = 12) and control subjects (n = 12
## Abstract In a randomised crossβover study we compared human isophane insulin (Human Insulatard^TM^) with human crystalline insulin zinc suspension (Human Ultratard^TM^) as longerβacting, nightβtime insulins given thrice daily soluble insulin in the management of diabetes. We studied 20 insulinβd